Sumanta K. Pal

34.0k total citations · 4 hit papers
741 papers, 17.4k citations indexed

About

Sumanta K. Pal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sumanta K. Pal has authored 741 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 488 papers in Pulmonary and Respiratory Medicine, 311 papers in Oncology and 259 papers in Molecular Biology. Recurrent topics in Sumanta K. Pal's work include Renal cell carcinoma treatment (379 papers), Cancer Genomics and Diagnostics (219 papers) and Bladder and Urothelial Cancer Treatments (169 papers). Sumanta K. Pal is often cited by papers focused on Renal cell carcinoma treatment (379 papers), Cancer Genomics and Diagnostics (219 papers) and Bladder and Urothelial Cancer Treatments (169 papers). Sumanta K. Pal collaborates with scholars based in United States, Canada and France. Sumanta K. Pal's co-authors include Toni K. Choueiri, Robert A. Figlin, Brian I. Rini, Elizabeth R. Plimack, Nazlı Dizman, Hua Yu, Ulka N. Vaishampayan, Mark D. Pegram, David F. McDermott and Daniel Y.C. Heng and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Sumanta K. Pal

692 papers receiving 17.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Padmanee Sharma, Andrea Necchi et al. profile →
Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study

2016 371 citations Sumanta K. Pal et al. Journal of Clinical Oncology profile →
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

2017 348 citations Hans J. Hammers, Elizabeth R. Plimack et al. Journal of Clinical Oncology profile →
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

2021 170 citations Sumanta K. Pal, Daniel Y.C. Heng et al. profile →

Peers

Countries citing papers authored by Sumanta K. Pal

Since Specialization

Citations

This map shows the geographic impact of Sumanta K. Pal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumanta K. Pal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumanta K. Pal more than expected).

Fields of papers citing papers by Sumanta K. Pal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumanta K. Pal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumanta K. Pal. The network helps show where Sumanta K. Pal may publish in the future.

Co-authorship network of co-authors of Sumanta K. Pal

This figure shows the co-authorship network connecting the top 25 collaborators of Sumanta K. Pal. A scholar is included among the top collaborators of Sumanta K. Pal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumanta K. Pal. Sumanta K. Pal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma 2025 ·Ulka N. Vaishampayan, Sumanta K. Pal, (unknown), Neha D. Shah, Dena Battle, Michael Staehler	0
2	The gut microbiome and dietary metabolites in the treatment of renal cell carcinoma 2024 ·Urologic Oncology Seminars and Original Investigations ·(unknown), (unknown), (unknown), Sumanta K. Pal	3
3	1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC) 2023 ·Annals of Oncology ·(unknown), Kosuke Takemura, Devon J. Boyne, Matthew T. Warkentin, Darren R. Brenner, (unknown), J. Connor Wells, Chris Labaki, Bradley A. McGregor, (unknown), Luís Meza, Sumanta K. Pal, Benoit Beuselinck, Rana R. McKay, Bernadett Szabados, Thomas Powles, Takeshi Yuasa, Leopold Ludwig, Toni K. Choueiri, (unknown)	2
4	Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy 2023 ·Hematology/Oncology Clinics of North America ·Regina Barragán-Carrillo, Ameish Govindarajan, (unknown), (unknown), Sumanta K. Pal	4
5	A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy 2023 ·The Oncologist ·Saro Kasparian, (unknown), Ni‐Chun Tsai, Joycelynne Palmer, Sumanta K. Pal, Yung Lyou, Tanya B. Dorff	7
6	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent 2021 ·Molecular Cancer Therapeutics ·Eddy S. Yang, Amin H. Nassar, Elio Adib, Opeyemi A. Jegede, Sarah Abou Alaiwi, (unknown), David A. Braun, Mahsa Zarei, Heng Du, Sumanta K. Pal, Gurudatta Naik, Guru Sonpavde	6
7	Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma 2020 ·European Urology Open Science ·J. Connor Wells, Shaan Dudani, Gan Chen, Igor Stukalin, Arun Azad, Elizabeth Liow, Frede Donskov, Takeshi Yuasa, Sumanta K. Pal, Gloria Velasco, Laura D. Wood, Aaron R. Hansen, Benoit Beuselinck, Christian Kollmannsberger, (unknown), Bradley A. McGregor, Mei Sheng Duh, Lynn Huynh, D.Y.C. Heng	1
8	425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents 2020 ·Annals of Oncology ·Gan Chen, Daniel E. Meyers, Igor Stukalin, Shaan Dudani, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Aliyah Pabani, Timothy Cheng, Takeshi Yuasa, Donald G. Morris, Ravindran Kanesvaran, Sumanta K. Pal, Lori Wood, Frede Donskov, Toni K. Choueiri, D.Y.C. Heng	2
9	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer 2019 ·Cancer ·Alberto Martini, Rachel Jia, Bart S. Ferket, Nikhil Waingankar, Elizabeth R. Plimack, Simon J. Crabb, Lauren C. Harshman, Evan Y. Yu, Thomas Powles, Jonathan E. Rosenberg, Sumanta K. Pal, Ulka N. Vaishampayan, Andrea Necchi, Peter Wiklund, Reza Mehrazin, Madhu Mazumdar, John P. Sfakianos, Matthew D. Galsky	26
10	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis 2019 ·European Urology Oncology ·Andrew W. Hahn, Zachary Klaassen, Neeraj Agarwal, Benjamin Haaland, (unknown), Xiang Y. Ye, Xuechen Wang, Sumanta K. Pal, Christopher J.D. Wallis	68
11	Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review 2018 ·The Oncologist ·Nizar M. Tannir, Sumanta K. Pal, Michael B. Atkins	55
12	discovery-of-resistance-pathways-to-fibroblast-growth-factor-receptor-inhibition-in-bladder-cancer/# 2017 ·Sumanta K. Pal, Miaoling He, Jeremy O. Jones, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
13	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study breakdown → 2017 ·Journal of Clinical Oncology ·Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin	348
14	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer 2017 ·OncoImmunology ·Saul J. Priceman, Ethan Gerdts, Dileshni Tilakawardane, (unknown), John P. Murad, Anthony K. Park, Brook Jeang, Yukiko Yamaguchi, Xin Yang, Ryan Urak, Lihong Weng, Wen-Chung Chang, Sarah Wright, Sumanta K. Pal, Robert E. Reiter, Anna M. Wu, Christine E. Brown, Stephen J. Forman	120
15	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer 2016 ·Journal of Oncology Practice ·Arti Hurria, Chie Akiba, Jérôme H. Kim, (unknown), Matthew Loscalzo, Vani Katheria, Marianna Koczywas, Sumanta K. Pal, Vincent Chung, Stephen J. Forman, Nitya Nathwani, Marwan Fakih, Chatchada Karanes, Dean Lim, Leslie Popplewell, Harvey Jay Cohen, Beverly Canin, David Cella, Betty Ferrell, Leanne Goldstein	65
16	Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors 2015 ·Clinical Cancer Research ·Sumanta K. Pal, (unknown), Xiwei Wu, Hanjun Qin, Marcin Kortylewski, Joann Hsu, (unknown), Paul Frankel	60
17	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients 2015 ·Clinical Cancer Research ·Dewan Md Sakib Hossain, Sumanta K. Pal, Dayson Moreira, Priyanka Duttagupta, Qifang Zhang, Haejung Won, Jeremy Jones, Massimo D’Apuzzo, Stephen J. Forman, Marcin Kortylewski	156
18	RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma 2014 ·Molecular Cancer Research ·Sumanta K. Pal, Miaoling He, Tommy R. Tong, Huiqing Wu, Xueli Liu, Clayton Lau, Jinhui Wang, Charles Warden, Xiwei Wu, Sabina Signoretti, Toni K. Choueiri, José A. Karam, Jeremy O. Jones	37
19	Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling 2013 ·Cancer Research ·Anne Schroeder, Andreas Herrmann, Gregory Cherryholmes, Claudia Kowolik, Ralf Buettner, Sumanta K. Pal, Hua Yu, Gerhard Müller‐Newen, Richard Jove	156
20	Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480 2011 ·Cancer Research ·Xin Hong, Andreas Herrmann, Karen L. Reckamp, Wang Zhang, Sumanta K. Pal, Michael Hedvat, Chunyan Zhang, Wei Liang, Anna Scuto, Shaobu Weng, Deborah Morosini, Zhu Cao, Michael Zinda, Robert A. Figlin, Dennis Huszar, Richard Jove, Hua Yu	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact